Pfizer Appoints BU Executives

Olivier Brandicourt has been appointed president and general manager of the Emerging Markets and Established Products Business Units at Pfizer. He succeeds David Simmons, who is leaving Pfizer to become the chairman and chief executive officer of PPD.
 
“Olivier is ideally suited to take on this new role,” said Ian Read, Pfizer chairman and chief executive officer. “He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today’s changing industry and healthcare landscape.”
 
He added, “We thank David for his contributions throughout his 15-year career at Pfizer. Under his leadership, the Established Products Business Unit was created, expanding Pfizer’s market reach while also helping to ensure patients have the access to high-quality, affordable medicines they need.”
 
Dr. Brandicourt has held senior positions at Pfizer across a range of disciplines. Most recently, he served as president and general manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team.
 
Also, John Young, regional president of Europe and Canada for the Primary Care business, has been appointed president and general manager of the Primary Care Business Unit and will join the Executive Leadership Team. Mr. Young has spent 25 years with Pfizer and held a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the UK.
 
“John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business. We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum,” Mr. Read noted.